- Home
- MPLN vs ADVM Comparison
MPLN vs ADVM Comparison
Compare MPLN & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPLN
- ADVM
- Stock Information
- Founded
- MPLN 1980
- ADVM 2006
- Country
- MPLN United States
- ADVM United States
- Employees
- MPLN 2800
- ADVM N/A
- Industry
- MPLN Business Services
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPLN Consumer Discretionary
- ADVM Health Care
- Exchange
- MPLN Nasdaq
- ADVM Nasdaq
- Market Cap
- MPLN 101.6M
- ADVM 119.6M
- IPO Year
- MPLN N/A
- ADVM 2014
- Fundamental
- Price
- MPLN $11.55
- ADVM $4.74
- Analyst Decision
- MPLN Hold
- ADVM Strong Buy
- Analyst Count
- MPLN 2
- ADVM 6
- Target Price
- MPLN $25.00
- ADVM $27.83
- AVG Volume (30 Days)
- MPLN 67.7K
- ADVM 229.5K
- Earning Date
- MPLN 11-05-2024
- ADVM 11-04-2024
- Dividend Yield
- MPLN N/A
- ADVM N/A
- EPS Growth
- MPLN N/A
- ADVM N/A
- EPS
- MPLN N/A
- ADVM N/A
- Revenue
- MPLN $942,614,000.00
- ADVM $1,000,000.00
- Revenue This Year
- MPLN N/A
- ADVM N/A
- Revenue Next Year
- MPLN $1.17
- ADVM N/A
- P/E Ratio
- MPLN N/A
- ADVM N/A
- Revenue Growth
- MPLN N/A
- ADVM N/A
- 52 Week Low
- MPLN $4.80
- ADVM $4.59
- 52 Week High
- MPLN $69.20
- ADVM $29.70
- Technical
- Relative Strength Index (RSI)
- MPLN 64.05
- ADVM 25.31
- Support Level
- MPLN $5.61
- ADVM $4.59
- Resistance Level
- MPLN $7.40
- ADVM $4.89
- Average True Range (ATR)
- MPLN 0.81
- ADVM 0.30
- MACD
- MPLN 0.16
- ADVM -0.06
- Stochastic Oscillator
- MPLN 97.45
- ADVM 5.56
About MPLN MultiPlan Corporation
MultiPlan Corp is a provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency, and fairness to the U.S. healthcare industry. The company interprets clients' needs and customizes solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.